Wenbo Sun

By |

Uncertainty quantification and decision making are increasingly demanded with the development of future technology in engineering and transportation systems. Among the uncertainty quantification problems, Dr. Wenbo Sun is particularly interested in statistical modelling of engineering system responses with considering the high dimensionality and complicated correlation structure, as well as quantifying the uncertainty from a variety of sources simultaneously, such as the inexactness of large-scale computer experiments, process variations, and measurement noises. He is also interested in data-driven decision making that is robust to the uncertainty. Specifically, he delivers methodologies for anomaly detection and system design optimization, which can be applied to manufacturing process monitoring, distracted driving detection, out-of-distribution object identification, vehicle safety design optimization, etc.

Steven J. Katz

By |

Dr. Katz’s research addresses cancer treatment communication, decision-making, and quality of care. His work aims to examine the dynamics of how precision medicine presents itself in the exam room via provider and patient communication and shared decision-making. Dr. Katz leads the Cancer Surveillance and Outcomes Research Team (CanSORT), an interdisciplinary research program centered at the University of Michigan and focused on population and intervention studies of the quality of care and outcomes of cancer detection and treatment in diverse populations.  Dr. Katz and CanSORT have been collaborating with Surveillance, Epidemiology, and End Results (SEER) cancer registries since 2002 to study breast cancer treatment decision making at the population level. We obtain patient clinical and demographic information from SEER and combine this with surveys of patients and physicians to create comprehensive data sets that enable us to study testing and treatment trends and the challenges of individualizing treatments for breast cancer patients. In 2015 we added a new dimension to our research by partnering with evaluative testing firms to obtain tumor genomic and germline genetic test results for over 30,000 breast and ovarian cancer patients in the states of California and Georgia. We are also pursuing insurance claims data to assist with our analysis of physician network effects.

Steven Katz, MD discusses BRCA and multigene sequence testing at the labs of Ambry Genetics.

Steven Katz, MD discusses BRCA and multigene sequence testing at the labs of Ambry Genetics.